Adamas Pharmaceuticals (ADMS) Receives a Hold from Needham

By Carrie Williams

In a report released today, Serge Belanger from Needham maintained a Hold rating on Adamas Pharmaceuticals (ADMSResearch Report). The company’s shares closed last Wednesday at $4.46.

According to TipRanks.com, Belanger is a 4-star analyst with an average return of 5.6% and a 51.0% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Collegium Pharmaceutical.

Currently, the analyst consensus on Adamas Pharmaceuticals is a Strong Buy with an average price target of $8.75.

See today’s analyst top recommended stocks >>

Adamas Pharmaceuticals’ market cap is currently $132.9M and has a P/E ratio of -2.10. The company has a Price to Book ratio of -3.76.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer’s disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.